Literature DB >> 27214756

Total Economic Consequences of an Influenza Outbreak in the United States.

Fynnwin Prager1,2, Dan Wei2,3, Adam Rose2,4.   

Abstract

Pandemic influenza represents a serious threat not only to the population of the United States, but also to its economy. In this study, we analyze the total economic consequences of potential influenza outbreaks in the United States for four cases based on the distinctions between disease severity and the presence/absence of vaccinations. The analysis is based on data and parameters on influenza obtained from the Centers for Disease Control and the general literature. A state-of-the-art economic impact modeling approach, computable general equilibrium, is applied to analyze a wide range of potential impacts stemming from the outbreaks. This study examines the economic impacts from changes in medical expenditures and workforce participation, and also takes into consideration different types of avoidance behavior and resilience actions not previously fully studied. Our results indicate that, in the absence of avoidance and resilience effects, a pandemic influenza outbreak could result in a loss in U.S. GDP of $25.4 billion, but that vaccination could reduce the losses to $19.9 billion. When behavioral and resilience factors are taken into account, a pandemic influenza outbreak could result in GDP losses of $45.3 billion without vaccination and $34.4 billion with vaccination. These results indicate the importance of including a broader set of causal factors to achieve more accurate estimates of the total economic impacts of not just pandemic influenza but biothreats in general. The results also highlight a number of actionable items that government policymakers and public health officials can use to help reduce potential economic losses from the outbreaks.
© 2016 Society for Risk Analysis.

Entities:  

Keywords:  Avoidance behavior; computable general equilibrium analysis; macroeconomic consequences; pandemic influenza; resilience

Mesh:

Substances:

Year:  2016        PMID: 27214756     DOI: 10.1111/risa.12625

Source DB:  PubMed          Journal:  Risk Anal        ISSN: 0272-4332            Impact factor:   4.000


  19 in total

1.  COVID-19, public agglomerations and economic effects: Assessing the recovery time of passenger transport services in Brazil.

Authors:  Admir Antonio Betarelli Junior; Weslem Rodrigues Faria; Andressa Lemes Proque; Fernando Salgueiro Perobelli; Vinicius de Almeida Vale
Journal:  Transp Policy (Oxf)       Date:  2021-06-14

2.  Could Covid-19 Worsen Food Insecurity in Burkina Faso?

Authors:  Patrice Rélouendé Zidouemba; Somlanare Romuald Kinda; Idrissa Mohamed Ouedraogo
Journal:  Eur J Dev Res       Date:  2020-10-26

3.  Pandemic risk: how large are the expected losses?

Authors:  Victoria Y Fan; Dean T Jamison; Lawrence H Summers
Journal:  Bull World Health Organ       Date:  2017-12-05       Impact factor: 9.408

4.  Influenza: National Trends Using the National Inpatient Sample Database from 1993 to 2015.

Authors:  Abdulrahman S Museedi; Mouhamed Nashawi; Abdullah Ghali; Aws Alameri; Abbas Alshami; Robert Nathanson
Journal:  Cureus       Date:  2020-04-16

5.  Completeness of open access FluNet influenza surveillance data for Pan-America in 2005-2019.

Authors:  Ryan B Simpson; Jordyn Gottlieb; Bingjie Zhou; Meghan A Hartwick; Elena N Naumova
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

6.  A Systematic Review of the Costs Relating to Non-pharmaceutical Interventions Against Infectious Disease Outbreaks.

Authors:  Janetta E Skarp; Laura E Downey; Julius W E Ohrnberger; Lucia Cilloni; Alexandra B Hogan; Abagael L Sykes; Susannah S Wang; Hiral Anil Shah; Mimi Xiao; Katharina Hauck
Journal:  Appl Health Econ Health Policy       Date:  2021-06-11       Impact factor: 3.686

Review 7.  Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications.

Authors:  Erin Sparrow; Martin Friede; Mohamud Sheikh; Siranda Torvaldsen; Anthony T Newall
Journal:  Vaccine       Date:  2016-09-09       Impact factor: 3.641

8.  Public Health-Driven Research and Innovation for Next-Generation Influenza Vaccines, European Union.

Authors:  Adoración Navarro-Torné; Finnian Hanrahan; Barbara Kerstiëns; Pilar Aguar; Line Matthiessen
Journal:  Emerg Infect Dis       Date:  2019-02       Impact factor: 6.883

Review 9.  Costs and benefits of interventions aimed at major infectious disease threats: lessons from the literature.

Authors:  Klas Kellerborg; Werner Brouwer; Pieter van Baal
Journal:  Eur J Health Econ       Date:  2020-08-13

10.  SARS-CoV-2 RapidPlex: A Graphene-Based Multiplexed Telemedicine Platform for Rapid and Low-Cost COVID-19 Diagnosis and Monitoring.

Authors:  Rebeca M Torrente-Rodríguez; Heather Lukas; Jiaobing Tu; Jihong Min; Yiran Yang; Changhao Xu; Harry B Rossiter; Wei Gao
Journal:  Matter       Date:  2020-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.